Brought to you by 
Vanguard Medica buys CNS biotech Cerebrus
07 May 2004
Executive Summary
Vanguard Medica (inlicenses early stage drugs) is buying Cerebrus (CNS therapeutics) in an all-stock transaction. Cerebrus shareholders will get 7.09mm Vanguard ordinary shares, valued at $15.37mm (UK9.6mm) at the time the deal was announced. After the merger Vanguard plans to change its name to Vernalis Group PLC.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vanguard Medica buys CNS biotech Cerebrus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice